platoseedplatoseed
The AI that delivers pharma R&D decisions in days, not months
Quinn makes the highest-stakes scientific decisions in drug development. Which drugs to bet on, what to develop next, how to get them to patients. In days instead of months.
Daniel Gomari is the founder and CEO of Quinn. A Stanford postdoc and PhD in Computational Biology, his work spanned ML for drug repurposing across cancer and metabolic disease, and multi-omics studies on aging and lifespan extension. He built Quinn after watching the pharma industry make billion-dollar R&D decisions on intuition and slide decks instead of computational evidence.
We help extend your healthspan by measuring 500+ molecules in your blood
iollo launches a subscription service that measures 500+ blood metabolites and uses the results to match users with personalized dietary, behavioral, and (coming soon) therapeutic action plans to influence aging and overall health. The service is at-home, with periodic testing and ongoing guidance for healthier aging.
From the original launch (Jul 2022) — may be outdated.
Formerly “iollo” · why startups rename →
Analyzing EHR and messaging data to predict disease before it occurs.
AI Agents for Pharma Drug Launches
